Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.
Hyperlipidemia: Are the PCSK9 inhibitors bouncing back?
This article, published by Pharma Times May 2019, considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.
The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products in multiple markets. These obstacles partly reflect initial premium pricing of the two available PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab). Price differentials have been all the more marked given the established reliability of low-cost, genericised statins as a tool for lowering cholesterol. In that light, many physicians, thought leaders and payers opted to wait for persuasive outcomes data that would substantiate the ability of the PCSK9 inhibitors to offset higher costs with long-term gains in preventing mortality, hospitalisation or other serious cardiovascular events.
China in the fast lane: Access opportunities for novel therapies in the world's hottest emerging market
In our latest article for pharmaphorum's Deep Dive magazine, Brett Gardiner and Boon Yap discuss access opportunities for novel therapies in the world’s hottest emerging market.
The sheer size of China’s population (1.4 billion) has long made it an attractive market for pharma in terms of potential volume, especially in the context of rising affluence associated with a growing middle class. In 2017, China was ranked the second largest pharmaceutical market in the world, behind the US. However, it has traditionally been a challenging market to launch into, particularly for manufacturers developing innovative and novel therapies. Recent changes to China’s regulations under its 2025 Made in China strategic plan – including an expedited market access process, more frequent updates to Reimbursed Drugs Listings and additional routes to reimbursement – look set to transform this paradigm and necessitate a reconsideration of manufacturers’ strategies to obtaining optimal pricing and reimbursement (P&R).
World Immunisation Week: Combating the rise of the anti-vaccination movement
Harrison Gaiger explores the rise of the anti-vaccination movement to understand what it has meant for global health, and outlines some of the initiatives that are aiming to combat vaccination hesitancy.
This week is World Immunisation Week, a public awareness event celebrated each year in the last week of April. The event aims to raise awareness and encourage people around the world to protect themselves and their families against vaccine-preventable diseases. However, for many people, immunisation programmes remain a highly contentious issue. In this article, I explore the rise of the anti-vaccination movement to understand what it has meant for global health, and outline some of the initiatives that are aiming to combat the dangers it presents.
In the hot seat with Colin Tan
We caught up with recently promoted Colin Tan from Research Partnership's Singapore office to find out more about life as a Research Manager, current projects he's working on, and what he thinks are the hottest healthcare trends in Asia.
Congratulations on your promotion! How have your responsibilities changed since being promoted from Research Executive to Research Manager? Thank you. The biggest change has been the added responsibility of leading project management, deliverables and client communication. However, some things don't change - teamwork remains key to success and I continue to learn and grow with every study.